Holen Sie sich die Stockscreener-App
45.97
2.79%
-1.3314
Schlusskurs vom Vortag:
$47.30
Offen:
$47.675
24-Stunden-Volumen:
2.63M
Relative Volume:
0.33
Marktkapitalisierung:
$18.25B
Einnahmen:
$2.23B
Nettoeinkommen (Verlust:
$-3.19B
KGV:
-5.6429
EPS:
-8.1462
Netto-Cashflow:
$-1.60B
1W Leistung:
-2.46%
1M Leistung:
-6.54%
6M Leistung:
+95.16%
1J Leistung:
+65.16%
1-Tages-Spanne:
$45.78
$47.73
1-Wochen-Bereich:
$43.68
$48.40
52-Wochen-Spanne:
$22.28
$59.55
Moderna Inc Stock (MRNA) Company Profile
Firmenname
Moderna Inc
Sektor
Branche
Telefon
(617) 714-6500
Adresse
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
46.00 | 18.77B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
420.30 | 109.34B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
702.59 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
796.07 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.83 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
294.34 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Equal Weight |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-12 | Eingeleitet | Jefferies | Hold |
| 2025-03-13 | Eingeleitet | Citigroup | Neutral |
| 2025-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Herabstufung | Goldman | Buy → Neutral |
| 2024-12-18 | Herabstufung | Argus | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-19 | Eingeleitet | Berenberg | Hold |
| 2024-11-18 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-09-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Herabstufung | Jefferies | Buy → Hold |
| 2024-09-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-11-03 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-06-26 | Hochstufung | UBS | Neutral → Buy |
| 2023-04-26 | Eingeleitet | Guggenheim | Neutral |
| 2023-03-13 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-02-24 | Herabstufung | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Hochstufung | Jefferies | Hold → Buy |
| 2022-12-14 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2022-01-26 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Eingeleitet | UBS | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Sell |
| 2021-10-15 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Bestätigt | Jefferies | Hold |
| 2021-02-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Herabstufung | Needham | Buy → Hold |
| 2020-11-23 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-11-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-07-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Argus | Buy |
| 2020-06-08 | Eingeleitet | Barclays | Overweight |
| 2020-04-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-05 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Moderna Inc Aktie (MRNA) Neueste Nachrichten
Brookline Capital Markets Weighs in on Moderna Q2 Earnings - MarketBeat
Moderna (MRNA) Receives a Buy from Piper Sandler - The Globe and Mail
Sigma Planning Corp Makes New $907,000 Investment in Moderna, Inc. $MRNA - MarketBeat
Abbas Hussain Sells 5,682 Shares of Moderna (NASDAQ:MRNA) Stock - MarketBeat
Moderna director Abbas sells $264,951 in shares - Investing.com
Sandra Horning at Moderna (NASDAQ: MRNA) gains 16,233 shares via RSU vesting - Stock Titan
Director Rubenstein acquires 8,116 Moderna (NASDAQ: MRNA) shares - Stock Titan
Tax-driven stock sale by Moderna (MRNA) director after RSU vesting - Stock Titan
Director at Moderna (MRNA) receives 16,233 shares as RSUs vest - Stock Titan
Director at Moderna (NASDAQ: MRNA) receives 12,174 vested shares - Stock Titan
MRNA Maintained by RBC Capital -- Price Target Raised to $38.00 - GuruFocus
Moderna (MRNA) director converts 4,058 RSUs into common stock - Stock Titan
Moderna shares rise as investors revisit Q1 results, pipeline milestones, and fresh price-target bumps - Quiver Quantitative
Pfizer vs Moderna: Only One Pharma Giant Is a Winner In The Post-Covid Era - Yahoo Finance
UBS Adjusts Price Target on Moderna to $45 From $36, Maintains Neutral Rating - marketscreener.com
Mitsubishi UFJ Trust & Banking Corp Boosts Stock Holdings in Moderna, Inc. $MRNA - MarketBeat
The Zacks Analyst Blog Highlights Moderna, Merck and Vertex Pharmaceuticals - The Globe and Mail
Brokers Issue Forecasts for Moderna FY2029 Earnings - MarketBeat
MRNA Q1 Deep Dive: International Partnerships and Pipeline Progress Offset Litigation Headwinds - Yahoo Finance
Moderna’s Stock Rises in 2026 as International COVID-19 Vaccine Sales Offset U.S. Decline - geneonline.com
Moderna’s strong vaccine sales outside US far surpass estimates - The Boston Globe
Moderna (MRNA) Is Down 10.6% After Q1 Loss Widened On Settlement And EU Vaccine Wins – Has The Bull Case Changed? - Yahoo Finance
ProShares Ultra S&P 500 Equal Weight's Moderna Inc(MRNA) Holding History - GuruFocus
Vanguard Group Inc. Purchases 399,487 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Q1 2026 Earnings Call Transcript - Insider Monkey
A Look At Moderna (MRNA) Valuation After Q1 2026 Earnings And New Vaccine Approvals - Yahoo Finance
Moderna Inc (MRNA) Q1 2026 Earnings Call Highlights: Strategic Growth Amidst Legal Challenges By GuruFocus - Investing.com Canada
Moderna Inc (MRNA) Q1 2026 Earnings Call Highlights: Strategic Growth Amidst Legal Challenges - GuruFocus
Moderna (MRNA) Reports Strong Q1 2026 Performance with $400 Million Revenue - GuruFocus
Research Alert: CFRA Maintains Hold Rating On Shares Of Moderna, Inc. After Q1 Earnings - Moomoo
Moderna, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Legal settlement drives Q1 2026 loss at Moderna (NASDAQ: MRNA) - Stock Titan
Moderna, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Moderna first-quarter revenue jumps on strong overseas COVID vaccine sales - The Economic Times
Moderna’s Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. - Barron's
Sector Update: Health Care Stocks Softer Friday Afternoon - Moomoo
Moderna, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:MRNA) 2026-05-01 - Seeking Alpha
Moderna’s first quarter 2026 sales well ahead of estimates - The Pharma Letter
RBC Capital raises Moderna stock price target on Q1 beat By Investing.com - Investing.com Canada
Biotech Stocks To Follow TodayMay 1st - MarketBeat
Moderna Reports Q1 Loss, Stock Jumps on Strong International Sales - The Globe and Mail
Moderna sees revenue bump from international COVID vaccine sales - BioPharma Dive
Moderna reports mixed Q1 results as revenue beats estimates but litigation charge weighs on earnings - Proactive financial news
[144] Moderna, Inc. SEC Filing - Stock Titan
BofA raises Moderna stock price target to $32 on Q1 beat - Investing.com
Moderna Sales Triple To $389 Million As Shares Rise 5.4% - GuruFocus
Moderna Q1 Earnings: Revenue Beat Overshadowed By Litigation Charge, Pipeline Drives Outlook - Seeking Alpha
Why Is Moderna Stock Falling Friday?Moderna (NASDAQ:MRNA) - Benzinga
Moderna Maintains 2026 Revenue Growth Outlook as First-Quarter Results Beat Estimates - marketscreener.com
Moderna Revenue Beat: Overseas Covid Shot Sales Jump, but $900 Million Charge Clouds the Turnaround - TechStock²
Finanzdaten der Moderna Inc-Aktie (MRNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.94%
1.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):